Korjuny

Catumaxomab, the active ingredient in Korjuny, is a monoclonal antibody presented as a solution for injection for intraperitoneal use. It is indicated for the management of malignant ascites associated with epithelial cancers in adult patients, helping to control fluid accumulation and improve quality of life.

GNH USA supplies Korjuny as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Customers benefit from reliable logistics and temperature‑controlled shipping where required.

Korjuny (catumaxomab) is used in the management of malignant ascites, a fluid accumulation condition linked to epithelial cancers that express EpCAM. Malignant ascites associated with epithelial cancers: reduces peritoneal fluid buildup and improves symptomatic relief. Ovarian carcinoma with malignant ascites: helps control peritoneal fluid and may improve patient comfort. Gastric carcinoma with malignant ascites: reduces ascitic volume and supports palliative management. Pancreatic carcinoma with malignant ascites: assists in decreasing fluid accumulation and alleviating symptoms. Other EpCAM‑positive epithelial cancers with malignant ascites: provides immunologic targeting to reduce fluid buildup. EpCAM‑positive colorectal carcinoma with malignant ascites: contributes to fluid reduction and symptom control.

Catumaxomab may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevated body temperature. - Abdominal pain: discomfort in the peritoneal region. - Nausea and vomiting: gastrointestinal upset. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Cytokine release syndrome: systemic inflammatory response that can be life‑threatening. - Severe infection: peritonitis or sepsis requiring hospitalization. - Allergic reactions: anaphylaxis or severe hypersensitivity. - Hepatic dysfunction: elevated liver enzymes or liver injury.

When using Korjuny, clinicians should observe specific precautions to ensure patient safety and product integrity.

Patient selection: confirm EpCAM‑positive tumor status before administration. Monitoring: observe for signs of cytokine release and manage fever promptly. Infection risk: assess for active infections and provide prophylactic measures as needed. Pregnancy and lactation: avoid use due to unknown safety profile in pregnant or breastfeeding women. Concomitant immunosuppression: evaluate risks when combined with other immunosuppressive agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Catumaxomab can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may trigger severe immune reactions. - Other monoclonal antibodies targeting immune cells: may increase risk of excessive immunosuppression. - High‑dose corticosteroids: can diminish therapeutic activity.

Moderate Interactions (Monitor Closely): - Chemotherapy agents: monitor for additive toxicity, especially hematologic effects. - Anticoagulants: watch for bleeding complications due to potential platelet activation changes. - Immunosuppressive drugs (e.g., azathioprine): may require dose adjustments.